Date of Award
Bachelor of Science Honours
School of Natural Sciences
Faculty of Computing, Health and Science
Dr Mary Boyce
Metabolomics is complementary to genomics, transcriptomics and proteomics; however, it has the capacity to reflect the activities of the organism at a functional level. Metabolomics can therefore be used as a diagnostic tool by identifying the up- or down-regulation of metabolites in the cell, tissue, plasma, serum or urine. Specifically, these are, but are not limited to, identifying biomarkers of disease, monitoring drug treatments, and monitoring surgical procedures such as organ transplant. Autosomal recessive polycystic kidney disease (ARPKD) makes up 5-8% of patients requiring kidney dialysis and/or transplantation and of these, an estimated 50% of patients progress to end-stage renal disease (ESRD) by the age of 10 years, resulting in renal and liver-related morbidity and mortality. The purpose of this research was to utilise the Lewis Polycystic Kidney (LPK) rat to investigate the ARPKD phenotype using metabolomics. Spot urine samples were collected from 7 male Lewis; 8 male LPK; and 6 female LPK rats aged 5 weeks. Metabolites were extracted from urine and derivatised for GC/MS analysis. The peak area of target components was normalised to the internal standard ribitol and then to creatinine. Principal component analysis (PCA) was used to visualise sample grouping and the loadings plot of the PCA was used to determine key metabolites attributed to the variance between sample groups. α-ketoglutarate, uric acid and allantoin were proposed as potential biomarkers for ARPKD in the 5-week old male LPK rat. The findings of this study, particularly the development of a GC/MS method to analyse Lewis and LPK rat urine, demonstrate the potential of metabolomics to further investigate ARPKD.
White, H. (2009). Metabolomic Investigation of a New Rat Model of Autosomal Recessive Polycystic Kidney Disease. Retrieved from http://ro.ecu.edu.au/theses_hons/1167